Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

A Board Member Bought Shares of Kronos Worldwide

Page 1 of 2

According to a filing with the SEC, Glenn Simmons, who serves on the Board of Directors at Kronos Worldwide, Inc. (NYSE:KRO) purchased 5,000 shares of the specialty chemicals company on January 19th at prices of about $19.20 per share. Simmons now owns over 48,000 shares of Kronos Worldwide, Inc. directly- so this purchase was a significant percentage increase in his holdings- and his spouse owns an additional 24,000 shares. Simmons was buying shares in November 2012 at prices around $13.30 per share; even though the stock is up 34% in the last three months, he apparently believes that it still has further to rise. See more of his insider trading activity and our history of insider purchases at Kronos. As of this writing, however, the stock price has increased further and is now at about $20 per share, a 4% increase from his most recent buy.

We track both varieties of insider trading, but insider purchases are particularly interesting. This is because insiders may sell for many reasons including diversification, but purchases are more likely to convey an insider’s feelings about the stock. Studies show that on average stocks bought by insiders outperform the market (read more about studies on insider trading).

Kronos Worldwide, Inc. is primarily a producer of titanium dioxide, which among other uses is an enhancer of coatings, plastics, and ceramics. Its recent rally reflects a perception that the company is set to recover from a poor 2012; the stock is actually down 8% from a year ago. The most recent data has 32% of the outstanding shares held short, however, so many market players- far from agreeing with Simmons that the stock will keep increasing in price- are in fact bearish. Looking at the company’s fundamentals, Kronos reported a 14% decrease in revenue in the third quarter of 2012 versus a year earlier and earnings were down almost 60%. At its current levels the stock trades at 15 times consensus earnings for 2013- that would be a fair price, with no particular attraction to the long or short side, but of course we wouldn’t take the precise numbers at face value. As a chemicals company, demand tends to be dependent on the broader economy and so the beta is 2.

How does Kronos compare to its peers?

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!